EIGR Eiger BioPharmaceuticals Inc.

$10.3 -7.62%

39,216 Shares Traded
71,145 Average Volume (last 30 days)

as of April 19, 2018 EST IEX Real-Time Price

Free Newsletter Sign Up

Short Pain Metrics

Approximate Amount of Money Shorts Have Made on the Day: $246.08 thousand
If Intiated on the First, Shorts Have Realized a Year to Date Return of:26.69%
If Intiated One Month Ago, Shorts Have Realized a Return of:-10.75%
If Initiated Five Days ago, Shorts Have Realized a Return of:5.07%
Peer Potential Short Squeezes Near Real Time Screener
*Please note the actual returns of shorts could be different as they started from different points.

Daily Indicators

Daily Short Pain Indicator [i] - Always Use Fundamentals on EverythingNeutral
200 Day Moving Average Indicator Bullish
50 Day Moving Average Indicator Bullish
52 Week High/Low Indicator Neutral

Short Stats

Short Percent to Float 2.8%
Short Interest289.51 thousand
Float10.33 million
Short Ratio4.6
Market Cap$108.42 million
Market Maker ActivityDaily Short Volume


Eiger's lonafarnib significantly reduced HDV in patients with low viral loads in mid-stage study; shares up 2% (SeekingAlpha)
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress(TM) 2018 (PR Newswire)
Biotech Forum: The Week Ahead (SeekingAlpha)
Eiger BioPharmaceuticals to Participate in Conferences in April (PR Newswire)
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia (PR Newswire)
Your Daily Pharma Scoop: Achaogen's Plazomicin, Eiger Provides Update On Llonafarnib, Eleven Biotherapeutics Obtains Funding (SeekingAlpha)
FDA signs off on single registration trial for Eiger Bio's lonafarnib in HDV; shares up 3% premarket (SeekingAlpha)
Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program (PR Newswire)
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March (PR Newswire)

Smart Money Sentiment

Institutional Ownership (Top 15 Funds) 67.9%
Insider Percent1.8%

Earnings Stats

PE Ratio -2.11
Dividend Yield 0%
Peer EarningsEarnings Calendar


200 Day Moving Average $10.28
50 Day Moving Average $9.5
52 Week High $16.2
52 Week Low $6.1

Data provided for free by IEX. Questions? Read the FAQ